Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
Dihydrotetrabenazine is an active metabolite of the vesicular monoamine transporter 2 (VMAT2) inhibitor tetrabenazine (Item No. 20380) that is generated by hepatic carbonyl reductases.1 Dihydrotetrabenazine binds to mouse pons medulla, hypothalamus, and striatum (Kds = 2.72, 2.28, and 2.4 nM, respectively) and inhibits synaptic vesicular serotonin (5-HT) uptake (IC50s = 2.2, 2.8, and 2.3 nM, respectively).2 It also binds to human caudate nucleus, hippocampus, and substantia nigra pars compacta (Kds = 2.9, 2.5, and 2.8 nM, respectively).3 Dihydrotetrabenazine stereoisomers bind to VMAT2 in rat striatum.4
WARNING This product is not for human or veterinary use.
1. Tetrabenazine for the treatment of hyperkinetic movement disorders: A review of the literature. Clin. Ther. 34(7), 1487-1504 (2012).
2. Dihydrotetrabenazine binding and monoamine uptake in mouse brain regions. J. Neurochem. 47(2), 331-339 (1986).
3. [3H]dihydrotetrabenazine, a new in vitro monoaminergic probe for human brain. J. Neurochem. 50(4), 1131-1136 (1988).
4. Preparation and evaluation of tetrabenazine enantiomers and all eight stereoisomers of dihydrotetrabenazine as VMAT2 inhibitors. Eur. J. Med. Chem. 46(5), 1841-1848 (2011).